Wellington Management Group LLP Lowers Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Wellington Management Group LLP decreased its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 51.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,261,480 shares of the biotechnology company's stock after selling 1,351,376 shares during the period. Wellington Management Group LLP owned about 2.08% of Ascendis Pharma A/S worth $188,352,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Janus Henderson Group PLC grew its holdings in shares of Ascendis Pharma A/S by 6.8% during the third quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company's stock worth $625,075,000 after buying an additional 267,881 shares in the last quarter. Avoro Capital Advisors LLC grew its position in shares of Ascendis Pharma A/S by 5.8% during the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company's stock worth $572,341,000 after acquiring an additional 229,995 shares during the last quarter. Westfield Capital Management Co. LP grew its position in Ascendis Pharma A/S by 3.4% in the 3rd quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company's stock valued at $766,523,000 after buying an additional 170,942 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in Ascendis Pharma A/S by 9.1% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company's stock valued at $278,760,000 after acquiring an additional 155,971 shares during the last quarter. Finally, Fred Alger Management LLC lifted its stake in Ascendis Pharma A/S by 65.0% during the second quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company's stock valued at $41,879,000 after buying an additional 120,952 shares in the last quarter.

Ascendis Pharma A/S Stock Down 0.4 %

Shares of NASDAQ:ASND traded down $0.58 during trading hours on Monday, hitting $132.42. 299,332 shares of the company's stock traded hands, compared to its average volume of 450,081. Ascendis Pharma A/S has a 1 year low of $101.43 and a 1 year high of $161.00. The business has a fifty day moving average price of $130.53 and a 200-day moving average price of $132.67.

Analysts Set New Price Targets

A number of research firms recently commented on ASND. Wells Fargo & Company increased their price objective on Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an "overweight" rating in a report on Tuesday, September 17th. TD Cowen reduced their target price on Ascendis Pharma A/S from $160.00 to $153.00 and set a "buy" rating for the company in a research report on Friday, November 15th. Stifel Nicolaus upped their price target on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a "buy" rating in a research report on Friday, November 15th. Bank of America boosted their price objective on Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a "buy" rating in a report on Monday, September 23rd. Finally, Oppenheimer lowered their price target on Ascendis Pharma A/S from $190.00 to $180.00 and set an "outperform" rating for the company in a research note on Friday, November 15th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $191.77.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.